Furthermore, when a combination therapy of antidiabetic agent, dipeptidyl peptidase-4 (DPP4) inhibitor, and MES + HS was performed in patients with T2DM, additive or synergistic effects were observed20. The gene discussed is DPP4; the disease is type 2 diabetes mellitus.